Joint Venture Sponsorship of Government Doctors
A pharmaceutical company is forming a 50/50 joint venture with a local partner in a country where doctors at public hospitals are government employees. The JV partner proposes a $250,000 'medical education fund' to sponsor 40 doctors to attend a conference at a resort. The partner says this is standard practice and that the JV agreement gives the partner control over marketing and events. The fund would be paid to an event organizer owned by the partner's cousin; the organizer has no website and provides only a one-page budget. The partner refuses to share the list of invited doctors or the selection criteria, saying it is 'commercially sensitive'. The company's compliance officer must advise the JV board before the first payment. The JV is important to the company's growth plan, and the partner has strong government relationships.
1. Assess the bribery risk of the proposed medical education fund and explain why the JV partner's control over marketing does not remove the company's responsibility.
Read the worked answer
The proposal has multiple high-risk features. The beneficiaries are government-employed doctors who can influence prescribing or purchasing decisions. The payment is a large sum to an event organizer owned by the partner's cousin, with no website and minimal budget documentation. The venue is a resort, which raises questions about whether the event is genuine education or hospitality designed to influence. The partner refuses to disclose the invitees or selection criteria, removing the ability to test whether the doctors are chosen for legitimate educational reasons. These are classic third-party and business-associate red flags.
The JV agreement may give the partner operational control over marketing, but the company cannot contract out of its ABMS responsibilities. The 2025 revision expands due diligence for business associates, including joint venture partners. The company is associated with the JV and may face legal, reputational, and certification risk if the fund is used for improper payments. The compliance officer should advise the JV board that partner control over events does not eliminate the need for transparency, due diligence, and approval.
2. What due diligence and control conditions should the compliance officer require before any payment is approved?
Read the worked answer
Before payment, the JV should conduct due diligence on the partner and the event organizer, including beneficial ownership, government connections, reputation, and track record. The organizer should provide a detailed agenda, budget, venue justification, and attendee selection criteria. The JV should verify that the doctors are selected on legitimate educational grounds and that the sponsorship complies with local law and applicable industry codes. The fee should be benchmarked against comparable events, and payment should go directly to legitimate vendors rather than to the partner or a cousin-owned intermediary without documentation.
Conditions should include a written sponsorship agreement with anti-bribery clauses, audit rights, transparency of attendee lists, no cash payments, and JV board approval. The company should have the right to review and approve the final attendee list and agenda. If the partner refuses transparency on ownership, attendees, or selection criteria, the compliance officer should recommend not paying. The JV board should document the risk assessment and the decision. Commercial importance and strong government relationships are reasons for more scrutiny, not less.
3. If the JV board decides to proceed, what monitoring and escalation measures should be in place?
Read the worked answer
Monitoring should include pre-payment verification of vendors and bank accounts, review of the final agenda and attendee list, confirmation that the event took place as described, and a post-event report with receipts and attendance records. The JV should audit the fund and test whether any doctors were selected because of their procurement influence. The company should have a whistleblowing channel available to JV staff and a protocol for escalating suspicious payments or requests. Compliance should review the relationship periodically and re-assess the partner's risk profile.
If monitoring identifies undisclosed beneficiaries, payments to unexplained intermediaries, or a sham event, the company should escalate to the JV board and its own board, suspend further funding, and consider legal advice and remediation. The decision file should show the conditions imposed, the approvals, and the monitoring results. This allows the company to demonstrate that it applied risk-based due diligence to a business associate and did not ignore red flags because of the partner's commercial or government connections.